Living Cell Technologies Ltd (ASX:LCT) Data Shows NTCELL Treatment Has Stopped
the Progression of Parkinsons
Auckland, New Zealand, Oct 27, 2015 - (ABN Newswire) - The four patients who
took part in Living Cell Technologies Limited's (ASX:LCT) (OTCMKTS:LVCLY)
Phase I/IIa clinical study of NTCELL(R) for Parkinson's disease have all
reached the milestone of 42 weeks post-implant. All four patients remain well,
and there are no safety concerns.
In all four patients NTCELL treatment has stopped the progression of
Parkinson's disease as measured by globally accepted and validated
neurological rating scales.
In all four patients the 42 week post-implant data show there is a clinically
and statistically significant improvement in the patients' neurological score
from their pre-implant baseline.
That improvement is equivalent to
approximately 5 years of Parkinson's disease remission and is maintained 74
weeks after NTCELL transplant in the first patient.
Data from the ongoing monitoring of the four patients was measured by
validated neurological rating scales and questionnaires, including the Unified
Parkinson's Disease Rating Scale (UPDRS), the Unified Dyskinesia Rating Scale
(UDysRS) and the Parkinson's Disease Quality of Life Questionnaire (PDQ-39).
These scales and questionnaires are used to assess improvements in patients'
movement abnormalities, other physical symptoms, well-being and ability to
perform everyday tasks.
Dr Ken Taylor, Chief Executive, says the continued improvement of the patients
is pleasing.
"We are delighted with the continued positive outcome of the study to date. It
certainly adds anticipation and motivation to the planned Phase IIb study. The
Phase IIb study will confirm the effective dose of NTCELL, define any placebo
component of the response and further identify the Parkinson's disease patient
sub group we would initially target."
About Living Cell Technologies Limited:
Living Cell Technologies Limited (ASX:LCT) is a New Zealand biotechnology
company focused on discovering, developing and commercialising regenerative
cell treatments which restore function using naturally occurring cells.
LCT’s lead product NTCELL(R) is an alginate coated capsule containing
clusters of neonatal porcine choroid plexus cells. After transplantation
NTCELL functions as a biological factory producing neurotrophic factors to
prevent and repair disease induced nerve degeneration.
The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of
Parkinson’s disease met the primary endpoint of safety and showed encouraging
clinical efficacy. A Phase IIb trial has been designed to further evaluate
NTCELLs potential as a disease-modifying treatment for patients with
Parkinson’
s disease.
NTCELL has the potential to be used in a number of other central nervous
system degenerative diseases such as Huntington’s, Alzheimer’s and motor
neurone diseases.
LCT is listed on the Australian (ASX:LCT) and US
(OTCMKTS:LVCLY) stock exchanges. The company is incorporated in Australia,
with its operations based in New Zealand.
Source:
Living Cell Technologies Limited
Contact
Ken Taylor
Chief Executive
Living Cell Technologies
T: +64 9 276 2690
M: +64 21 796000
E: [email protected]
LCT Price at posting:
6.9¢ Sentiment: Buy Disclosure: Held
